Yu-Luan Chen

No ORCID on file · 1 paper in corpus · active 2025

Study types

  • other 1

Condition tags

  • endometriosis 1
other 2025
Pharmacology research & perspectives ·doi:10.1002/prp2.70067

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the treatment o…